ATHA סך נכסי הפעילות העסקית Athira Pharma Inc

Athira Pharma, Inc. (ATHA) specializes in developing innovative therapies for nervous system diseases. The visualization of the total asset market value, which stands at 58.14, reflects the company's financial condition, which depends on the outcomes of Alzheimer's drug trials and capital volume. The business potential relies on unique molecules that restore neural connections via the HGF/MET pathway, providing significant pricing power. Management is currently revising the development vector following the failure of the primary drug.

To objectively assess the stability of Athira Pharma, Inc. (ATHA), investors must analyze the volume of resources, calculated inversely via return on assets (ROA), to track capital dynamics between reports. The trajectory of total assets (via ROA) demonstrates the effectiveness of cost restructuring and the company's ability to fund the development of second-generation molecules amid a strategic transition following the failures of its flagship drug.